Trial Profile
Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Mar 2024
Price :
$35
*
At a glance
- Drugs Hemay 022 (Primary) ; Exemestane; Fulvestrant; Letrozole
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions
- Sponsors Tianjin Hemay Pharmaceutical Sci-Tech
- 09 Dec 2023 Status changed from recruiting to completed.
- 09 Dec 2023 Results assessing Antitumor efficacy and safety of sacibertinib in combination with endocrine therapy,presented at the 46th Annual San Antonio Breast Cancer Symposium
- 27 Apr 2021 Planned End Date changed from 7 Jul 2021 to 7 Dec 2022.